Latest news with #EuronextParis
Yahoo
3 days ago
- Business
- Yahoo
Quadient Advances AI Capabilities to Help Organizations Power Better Customer Interactions and Revenue Growth
Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announces the release of advanced AI capabilities designed for crafting and orchestrating highly personalized, omnichannel customer interactions. The extended AI is part of the latest release of Quadient Inspire, an industry-leading customer communications management (CCM) solution, and represents Quadient's continued investment in transforming the way businesses dynamically communicate with customers. New AI-driven capabilities include real-time sentiment analysis and scoring, language translation and personally identifiable information (PII) detection. The new advancements enable businesses to deliver seamless, effective and meaningful interactions to their customers while empowering employees to create and improve communications effortlessly. With the integration of advanced AI assistance, Quadient Inspire now empowers organizations to achieve up to 50% faster content creation and double communication output without increasing headcount. By guiding authors with real-time suggestions, Inspire dramatically accelerates time-to-market while improving consistency, quality and regulatory alignment across all customer communications. 'Quadient Inspire has evolved significantly, leveraging AI capabilities for faster content creation and refinement, high-level personalization, language translation and automation of sophisticated workflows,' said Robert Palmer, research VP with IDC's imaging, printing, and document solutions group. 'The latest Inspire release includes expanded cloud environment options, supporting Quadient's AnyPrem promise. Quadient continues to innovate, setting a high standard for customer communication management in an increasingly dynamic digital environment.' 'Quadient is always striving for new heights in CCM leadership, and we're excited to be reshaping the industry with the new opportunities AI and automation provide," said Chris Hartigan, chief solution officer, digital, Quadient. 'Our strategy for driving innovation is focused on elevating customer interactions, streamlining and automating workflows, discovering actionable insights, ensuring regulatory adherence and driving better business outcomes. Quadient's intelligent platform is helping businesses tackle some of the biggest mountains they face today – measuring, optimizing and driving value with intelligent, personalized customer communications.' The latest release of Quadient Inspire (R17) includes more than 300 enhancements, offering advanced content management like importing the latest InDesign and Quark files, leveraging PDF Forms support and utilizing track changes to enhance collaboration and compliance. To strengthen regulatory compliance, Inspire includes a variety of features to simplify the design of accessible communications, with an automated PDF accessibility tool that remediates legacy documents on-demand or in high-volume batches by applying accessibility templates. Additionally, the latest Quadient Inspire release supports even more cloud environments for seamless deployment. For more information on Quadient Inspire, visit: About Quadient®Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit ContactsJoe Scolaro, Quadient Global Press Relations Manager +1 203-301-3673 jscolaro@ Kiley Ribordy, Walker Sands Senior PR Director quadientpr@ Attachment PR Quadient Inspire R17 and AI_EN_v1Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Quadient Advances AI Capabilities to Help Organizations Power Better Customer Interactions and Revenue Growth
Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announces the release of advanced AI capabilities designed for crafting and orchestrating highly personalized, omnichannel customer interactions. The extended AI is part of the latest release of Quadient Inspire, an industry-leading customer communications management (CCM) solution, and represents Quadient's continued investment in transforming the way businesses dynamically communicate with customers. New AI-driven capabilities include real-time sentiment analysis and scoring, language translation and personally identifiable information (PII) detection. The new advancements enable businesses to deliver seamless, effective and meaningful interactions to their customers while empowering employees to create and improve communications effortlessly. With the integration of advanced AI assistance, Quadient Inspire now empowers organizations to achieve up to 50% faster content creation and double communication output without increasing headcount. By guiding authors with real-time suggestions, Inspire dramatically accelerates time-to-market while improving consistency, quality and regulatory alignment across all customer communications. 'Quadient Inspire has evolved significantly, leveraging AI capabilities for faster content creation and refinement, high-level personalization, language translation and automation of sophisticated workflows,' said Robert Palmer, research VP with IDC's imaging, printing, and document solutions group. 'The latest Inspire release includes expanded cloud environment options, supporting Quadient's AnyPrem promise. Quadient continues to innovate, setting a high standard for customer communication management in an increasingly dynamic digital environment.' 'Quadient is always striving for new heights in CCM leadership, and we're excited to be reshaping the industry with the new opportunities AI and automation provide," said Chris Hartigan, chief solution officer, digital, Quadient. 'Our strategy for driving innovation is focused on elevating customer interactions, streamlining and automating workflows, discovering actionable insights, ensuring regulatory adherence and driving better business outcomes. Quadient's intelligent platform is helping businesses tackle some of the biggest mountains they face today – measuring, optimizing and driving value with intelligent, personalized customer communications.' The latest release of Quadient Inspire (R17) includes more than 300 enhancements, offering advanced content management like importing the latest InDesign and Quark files, leveraging PDF Forms support and utilizing track changes to enhance collaboration and compliance. To strengthen regulatory compliance, Inspire includes a variety of features to simplify the design of accessible communications, with an automated PDF accessibility tool that remediates legacy documents on-demand or in high-volume batches by applying accessibility templates. Additionally, the latest Quadient Inspire release supports even more cloud environments for seamless deployment. For more information on Quadient Inspire, visit: About Quadient®Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit ContactsJoe Scolaro, Quadient Global Press Relations Manager +1 203-301-3673 jscolaro@ Kiley Ribordy, Walker Sands Senior PR Director quadientpr@ Attachment PR Quadient Inspire R17 and AI_EN_v1Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET. The fireside chat will be webcast live and will be accessible in the investors section of Inventiva's investor page: The replay of the webcast will be available on Inventiva's website for approximately six months. Inventiva's management will also participate in the UBS Spring Biotech Conference which will take place in New York on June 24th, 2025. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Inventiva Pascaline ClercEVP, Strategy and Corporate Affairsmedia@ +1 202 499 8937 Brunswick GroupTristan Roquet Montegon /Aude Lepreux /Julia CailleteauMedia relationsinventiva@ +33 1 53 96 83 83 ICR HealthcarePatricia L. BankInvestor relations +1 415 513 1284 Attachment Inventiva - PR - June Investors Conferences - EN - 05 27 2025
Business Wire
4 days ago
- Business
- Business Wire
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below. Jefferies Global Healthcare Conference Dates: June 3 – 5 2025 | New York, USA The executive team will participate in a fireside chat scheduled on Thursday, June 5, 2025, from 7:35 to 8:05 am EDT. Goldman Sachs 46 th Annual Global Healthcare Conference Dates: June 9 – 11 2025 | Miami, USA The executive team will participate in a fireside chat scheduled on Tuesday, June 10, 2025, from 4:00 to 4:35 pm EDT. In addition, members of the executive team will participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30 to June 3, 2025 in Chicago, Illinois. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Mayor
5 days ago
- Business
- Business Mayor
Amundi joins in European defence ETF trend
The Amundi Stoxx Europe Defense UCITS ETF will track the STOXX Europe Total Market Defense Capped index, investing in firms with revenue exposure to defence activities. WisdomTree Defence ETF most successful passive launch in firm's history Initially launching on the Euronext Paris market, it will 'soon' be available on the Xetra and Borsa Italiana exchange, but there is no word yet on a London listing, however Amundi was contacted to clarify. This is the latest in a recent flurry of tracker products focused on European defence, with WisdomTree leading the charge back in April. …
